Fig 1.
Flow diagram of the study population.
This cohort study used customized Korean claims data from the NHIS database. Patients with T2DM who newly initiated dapagliflozin or empagliflozin as an add-on to metformin between 2014 and 2019 were identified. After applying predefined exclusion criteria, 9,109 eligible patients remained, including 5,580 treated with dapagliflozin and 3,529 with empagliflozin. aCVEs include ischemic heart diseases (I20–I25), coronary revascularization (procedure codes: M6551, M6552, M6561, M6563, M6564, M6571, M6572, O1641, O1642, O1647, OA641, OA642, and OA647), heart failure (I50), cerebrovascular disease (I60–I69), or transient cerebral ischemic attack (G45). Abbreviations: BMI, body mass index; CVEs, cardiovascular events; DPP-4is, dipeptidyl peptidase-4 inhibitors; GLP-1RAs, glucagon-like peptide-1 receptor agonists; SUs, sulfonylureas; T2DM, type 2 diabetes mellitus; TZDs, thiazolidinediones.
Table 1.
Baseline characteristics of dapagliflozin and empagliflozin groups.
Table 2.
Risk comparison of ischemic CVD events between dapagliflozin and empagliflozin groups.